We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AnaptysBio, Inc. (ANAB - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AnaptysBio, Inc. is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AnaptysBio, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for ANAB's full-year earnings has moved 27.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ANAB has gained about 43.9% so far this year. Meanwhile, the Medical sector has returned an average of -7.9% on a year-to-date basis. This means that AnaptysBio, Inc. is outperforming the sector as a whole this year.
Coherus Oncology (CHRS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 21.8%.
For Coherus Oncology, the consensus EPS estimate for the current year has increased 24% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AnaptysBio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 433 individual companies and currently sits at #143 in the Zacks Industry Rank. This group has lost an average of 2.4% so far this year, so ANAB is performing better in this area. Coherus Oncology is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on AnaptysBio, Inc. and Coherus Oncology as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has AnaptysBio, Inc. (ANAB - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
AnaptysBio, Inc. is a member of the Medical sector. This group includes 889 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AnaptysBio, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for ANAB's full-year earnings has moved 27.4% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ANAB has gained about 43.9% so far this year. Meanwhile, the Medical sector has returned an average of -7.9% on a year-to-date basis. This means that AnaptysBio, Inc. is outperforming the sector as a whole this year.
Coherus Oncology (CHRS - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 21.8%.
For Coherus Oncology, the consensus EPS estimate for the current year has increased 24% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, AnaptysBio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 433 individual companies and currently sits at #143 in the Zacks Industry Rank. This group has lost an average of 2.4% so far this year, so ANAB is performing better in this area. Coherus Oncology is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on AnaptysBio, Inc. and Coherus Oncology as they attempt to continue their solid performance.